PharmTech Drug Digest 11.20
News|Articles|September 1, 2016

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-09-07-2016
  • Volume 11
  • Issue 9

Regis Technologies Reports Successful FDA Inspection

FDA found no observations during recent inspection of Regis Technologies manufacturing site.

Regis Technologies has announced that no Form 483 observations were issued following a recent 12-day inspection by FDA of the quality and production systems at its Chicago-area facility.  The inspection was a routine quality systems inspection to support Regis’ FDA registration and ongoing manufacture of clinical and commercial APIs, according to a Aug. 25, 2016 company statement.

Regis provides synthesis, separations, and manufacturing services to pharmaceutical and biotechnology companies from its 36,000-sq-ft facility.

The company works with high value intermediates and APIs from process development and scale-up through validation and commercial manufacturing. The company also offers pharmaceutical regulatory support services, and access to its proprietary innovative chromatography products and services.

Source: Regis Technologies

 

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.